Clinical Trials Logo

Mouth Diseases clinical trials

View clinical trials related to Mouth Diseases.

Filter by:

NCT ID: NCT03679988 Not yet recruiting - Oral Disease Clinical Trials

Prevalence of Oral Mucosal Alterations in Mucocutaneous Ocular Disorders

Start date: October 2018
Phase:
Study type: Observational

The patients will be selected from the pool of the Clinics (Rheumatology, Ophthalmology and Dermatology) of Faculty of Medicine and (Diagnostic center and Oral Medicine) of Faculty of Dentistry -Cairo University. For each eligible participant, a full history will be obtained followed by thorough clinical examination.

NCT ID: NCT03671551 Not yet recruiting - Clinical trials for Psychomotor Development Impaired

Study of Psychomotor Development and Attachment in Children Aged 6 to 30 Months With Oral Disorder

TODEVA
Start date: September 2018
Phase:
Study type: Observational

Dietary difficulties and eating disorders of the child are a common reason for consulting infants and young children. There is currently little data on the psychomotor development of these children and their association with parent-child attachment. The objective of this study is to evaluate, at the same time, the three physiological, psychomotor and attachment dimensions of children with eating disorders.

NCT ID: NCT03670797 Not yet recruiting - Diabetes Clinical Trials

Prevalence Of Oral Mucosal Alterations In Diabetes Mellitus Type2

Start date: October 2018
Phase:
Study type: Observational

There are severe deficiency of database concerning the oral health status in Egyptian patients with Diabetes type 2. Our aim in the present study is to study the prevalence of oral mucosal alterations in type 2 DM patients and the effect of hyperglycemia on these alterations in controlled and uncontrolled patients to increase their awareness and minimize all the possible risk factors,to achieve a proper management for all oral problems.

NCT ID: NCT03582761 Not yet recruiting - Clinical trials for Hand, Foot and Mouth Disease

Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71

Start date: August 2018
Phase: Phase 4
Study type: Interventional

This study is a multicenter, case-control phase IV clinical trial to evaluate the effectiveness of the EV71 vaccine. About 40000 children in the town aged 6-35 months will be recruited and vaccinated with EV71 vaccines, which account for 20-40% of the children aged 6-35 months in the areas. The subjects will be vaccinated with EV71 vaccine at day 0 and day 28. Other children of appropriate age in the town will choose voluntarily whether or not to be vaccinated with EV71 vaccine. All children's vaccination of EV71 vaccines will be recorded in the study areas and the coverage rate of EV71 vaccine in the town will be calculated. The vaccination is expected to complete before the epidemic peak of HFMD. Surveillance of HFMD cases caused by EV71 will be conducted in hospitals of the study areas for 10-12 months, which cover a whole HFMD epidemic period. Throat and anal swabs will be collected from children with a clinical diagnosis of HFMD for typing of human enteroviruses tests by PCR. The HFMD cases with EV71 positive will be recruited as cases, while those with EV71 negative will be recruited as test-negative controls. Besides, for each EV71-associated HFMD cases, the investigators will match 2 community controls by age, sex and residence. There will be an immunogenic subgroup involving 2400 participants. In this subgroup, subjects will be randomly assigned to receive one of the three different batches of EV71 vaccines.

NCT ID: NCT03438045 Recruiting - Dental Caries Clinical Trials

Implementing a Participatory, Multi-level Intervention to Improve Asian American Health Study

Start date: May 9, 2018
Phase: N/A
Study type: Interventional

This feasibility and acceptability study will be conducted at 3 community outreach centers serving an urban, low-income Chinese population. The study will evaluate the feasibility and acceptability of implementing a partnered intervention to improve the oral and general health of low-income, urban Chinese American adults and of using remote data entry into an electronic health record (EHR). The research staff will survey a sample of Chinese American patients screened at each center about their satisfaction with the partnered intervention and about their oral health behaviors. An additional sample selected from providers [dentists and community health workers (CHW)], research staff, New York University (NYU) administrators, site directors, and community advisory board (CAB) members will participate in structured interviews about the partnered intervention. The remote EHR evaluation will include group adaptation sessions and workflow analyses via multiple recorded sessions with research staff, NYU administrators, outreach site directors, and providers (dentists and CHWs). The study will also model knowledge held by these non-patient participants (including CAB members) to evaluate and enhance the partnered intervention during and/or after the feasibility and acceptability study for use in future implementations.

NCT ID: NCT03429829 Recruiting - Dental Caries Clinical Trials

Caries Prophylaxis With Flairesse Fluoride Varnish

Start date: February 12, 2018
Phase: N/A
Study type: Interventional

Clinical study to evaluate the efficiency of Flairesse fluoride varnish in improving dental health in South African school children.

NCT ID: NCT03296410 Enrolling by invitation - Clinical trials for Hand, Foot and Mouth Disease (HFMD)

The Phase IVd of Inactivated Enterovirus 71 Vaccine

Start date: September 14, 2017
Phase: Phase 4
Study type: Interventional

Enterovirus 71 (EV71), a major pathogen causing hand-foot-and-mouth disease (HFMD) worldwide, is a member of the Human Enterovirus species A, family Picornaviridae. Its infection occasionally leads to severe diseases and death, with central nervous system (CNS) damage. Recently, except of inactivated vaccine, several EV71 vaccine candidates have been evaluated in animals but no final results of clinical trials, such as attenuated vaccine, subunit vaccine. A formalin-inactivated EV71 vaccine (Human Diploid cell, KMB-17 Cell) has been finished phase I, II and III clinical trials and licensed by SFDA in China at Dec. 3, 2015. Based on the results of clinical trials, the protective efficacy of inactivated EV71 vaccine is 97% against HFMD caused by EV71. The phase IV clinical trial has been carried out from July 2016. The purpose of phase IVd is to evaluated the immunogenicity and safety of the inactive EV71 vaccine within two measles attenuated live vaccine and live attenuated Japanese encephalitis vaccine at the same time point in large scale population of Chinese children (8 months old) in Guangdong Province, China.

NCT ID: NCT03281174 Completed - Clinical trials for Hand, Foot and Mouth Disease

Five-year Immune Persistence Study of Inactivated Enterovirus Type 71 (EV71) Vaccine

Start date: May 20, 2017
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the 5-year Immune Persistence of Inactivated Enterovirus Type 71 (EV71) Vaccine manufactured by Sinovac (Beijing) Biotech Co., Ltd.

NCT ID: NCT03278132 Recruiting - Clinical trials for Hand, Foot and Mouth Disease

Phase IV Clinical Trial, Immunogenicity and Safety of EV71 Vaccine

Start date: July 16, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the immunogenicity and safety of EV71 vaccine in infants aged 6 to 35 months old, by detecting the dynamic changes of neutralizing antibody at different time after vaccination

NCT ID: NCT03274102 Recruiting - Clinical trials for Hand, Foot and Mouth Disease

Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines

Start date: April 22, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the safety and immunogenicity of concomitant administration of EV71 vaccine with recombinant hepatitis B vaccine/Group A meningococcal polysaccharide vaccine.